Position of the Transparency Council – Rozebalamin (mecobalamin)
At its meeting on 27 January 2025, the Transparency Council adopted position No. 16/2025 on the legitimacy of issuing approvals for reimbursement of the drug Rozebalamin (mecobalamin) for the indication: amyotrophic lateral sclerosis.
Publication of the position >>